XML 52 R17.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Equity | 6 Months Ended
--- | ---
Jun. 30, 2017
Equity [Abstract] |
Equity | Equity Total equity as of June 30, 2017, decreased $555.0 million compared to December 31, 2016. This decrease was primarily driven by share repurchases totaling approximately $1.4 billion, as described below, and an adjustment to retained earnings of $852.8 million reflecting the spin-off of our hemophilia business, as described in Note 3, Hemophilia Spin-Off, to these condensed consolidated financial statements. These decreases were partially offset by net income attributable to Biogen Inc. of $1.6 billion. Share Repurchases In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired 2.9 million and 3.7 million shares of common stock at a cost of $781.8 million and $1.0 billion during the three and six months ended June 30, 2017, respectively. As of June 30, 2017, approximately $3.0 billion remains available to repurchase shares under this authorization. In February 2011 our Board of Directors authorized a program to repurchase up to 20.0 million shares of common stock, which was completed as of March 31, 2017. During the six months ended June 30, 2017, we repurchased 1.3 million shares of common stock at a cost of $365.4 million under this program. During the three and six months ended June 30, 2016, we did not repurchase any shares of common stock under this program. Noncontrolling Interests The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2017 |  | 2016 |  | 2017 |  | 2016
NCI, beginning of period | $ | (11.6 | ) |  | $ | 1.3 |  |  | $ | (11.5 | ) |  | $ | 2.1 |
Net income (loss) attributable to NCI, net of tax | — |  |  | (1.4 | ) |  | (0.1 | ) |  | (3.1 | )
Fair value of net assets and liabilities acquired and assigned to NCI | — |  |  | — |  |  | — |  |  | 0.9 |
NCI, end of period | $ | (11.6 | ) |  | $ | (0.1 | ) |  | $ | (11.6 | ) |  | $ | (0.1 | )

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration